DBP International AB: favorable response for SI-053 from The Ethics Commission of the Faculty of Medicine of Cologne University in Germany has been received
Double Bond Pharmaceutical International AB (publ) ("DBP") is about to take a very important step towards the start of clinical trial phase 1 in Germany of its front-line product SI-053 in patients with glioblastoma – a positive response from The Ethics Commission of the Faculty of Medicine of Cologne University (Central Ethics Committee, CEC) in Germany has now been received. This favorable approval is conditional in nature, and DBP is currently revising Informed Consent form and supporting forms with minor changes as per the recommendation from the CEC. Germany is accordingly the second